Product Profile - Overview


	ASAQ to treat malaria = Fixed dose combination of Artesunate + Amodiaquine

Launched in 2007 The concrete results of an innovative partnership between DNDi and Sanofi Meets the latest WHO guidelines for malaria treatment in Africa Simple regimen: 1 or 2 tablets once a day for 3 days Available at only 0.5$ for children, 1$ for adults Meets the highest standard of quality Made in the South for use in the South: ASAQ is produced in Marocco Available under the name Artesunate-Amodiaquine Winthrop (ASAQ) for public market and Coarsucam for private market Download ASAQ Press pack, March 1st 2007 [PDF 890KB] Download ASAQ Newsletter, November 2009 [PDF 980KB] Read more about ASAQ project		ASAQ News
		Implementation progress More than 200 million treatments distributed ASAQ registered in 33 countries Technology transfer to African industry partner ongoing
		Recent Scientific Publications Malaria Journal, March 2012 Artesunate-amodiaquine fixed dose combination for the treatment of Plasmodium falciparum malaria in India Malaria Journal, January 2012 Comparing changes in haematologic parameters occuring in patients included in randomized controlled trials of artesunate-amodiquine vs single and combination treatments of falciparum in sub-Saharan Africa
		Recent Events No recent ASAQ events

Except where otherwise noted, content on this site is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 2.5 Switzerland License